1. An antibody that specifically binds to denatured CD70 on a fixed line of SK-OV-3 or pancreatic cancer pancreatic cancer cells PANC-1 compared to binding to native CD70. ! 2. The antibody according to claim 1, which is a chimeric or humanized antibody. ! 3. The antibody according to claim 1, which binds to denatured CD70 on formalin-fixed paraffin-embedded cells or tissues with specific binding that is the same or better than that of the SG-21.1C1 antibody that is produced by the hybridoma deposited in ATCC and with Assigned Inventory No. PTA-8733, or antibody SG-21.5D12, which produces a hybridoma deposited in ATCC and with designated inventory No. PTA-8734. ! 4. The antibody according to claim 1, which competes for specific binding to denatured CD70 with the SG-21.1C1 antibody, which produces a hybridoma deposited in ATCC and with designated inventory No. PTA-8733, or with antibody SG-21.5D12, which produces a hybridoma deposited in ATCC and with designated inventory No. PTA-8734. ! 5. The antibody according to claim 4, which is an antibody SG-21.1C1, which produces a hybridoma deposited in ATCC and with designated inventory No. PTA-8733 or antibody SG-21.5D12, which produces a hybridoma deposited in ATCC and with designated inventory No. PTA-8734. ! 6. The antibody according to claim 4, containing the variable region of the heavy chain, which is at least 90% identical to the sequence of the variable region of the heavy chain of the antibody SG-21.1C1, and the variable region of the light chain, which is at least 90% identical to the sequence of the variable region light chain antibodies SG-21.1C1. ! 7. The antibody according to claim 4, containing a variable region1. Антитело, которое специфически связывается с денатурированным CD70 на фиксированной линии клеток злокачественной опухоли яичников SK-OV-3 или поджелудочной железы PANC-1 по сравнению со связыванием с нативным CD70. ! 2. Антитело по п.1, которое представляет собой химерное или гуманизированное анти
